Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells.
Ma L, Ramasubramanian R, Mehta N, Cossette B, Morgan D, Sukaj I, Bergaggio E, Kadauke S, Myers R, Paruzzo L, Ghilardi G, Grzywa T, Cozzone A, Schuster S, Frey N, Zhang L, Yousefpour P, Abraham W, Suh H, Ruella M, Grupp S, Chiarle R, Wittrup KD, Irvine DJ. Ma L, et al. Among authors: paruzzo l. bioRxiv [Preprint]. 2024 Apr 30:2024.04.16.589780. doi: 10.1101/2024.04.16.589780. bioRxiv. 2024. PMID: 38659938 Free PMC article. Preprint.
Efficacy and safety of bendamustine for lymphodepletion before lisocabtagene maraleucel.
Ghilardi G, Paruzzo L, Patel V, Svoboda J, Chong ER, Fardella E, Chong EA, Gabrielli G, Nasta SD, Landsburg DJ, Carter J, Pajarillo R, Barta SK, White G, Weber E, Napier E, Porter DL, Garfall AL, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: paruzzo l. J Hematol Oncol. 2024 Apr 22;17(1):19. doi: 10.1186/s13045-024-01542-9. J Hematol Oncol. 2024. PMID: 38644469 Free PMC article.
Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma.
Chong EA, Chong ER, Therwhanger D, Nasta SD, Landsburg DJ, Barta SK, Svoboda J, Gerson JN, Ghilardi G, Paruzzo L, Fraietta JA, Weber E, Stefano N, Porter DL, Frey NV, Garfall AL, Ruella M, Schuster SJ. Chong EA, et al. Among authors: paruzzo l. Transplant Cell Ther. 2024 Mar 16:S2666-6367(24)00288-4. doi: 10.1016/j.jtct.2024.03.015. Online ahead of print. Transplant Cell Ther. 2024. PMID: 38494076
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, Svoboda J, Nasta SD, Ugwuanyi OH, Landsburg DJ, Fardella E, Waxman AJ, Chong ER, Patel V, Pajarillo R, Kulikovskaya I, Lieberman DB, Cohen AD, Levine BL, Stadtmauer EA, Frey NV, Vogl DT, Hexner EO, Barta SK, Porter DL, Garfall AL, Schuster SJ, June CH, Ruella M. Ghilardi G, et al. Among authors: paruzzo l. Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24. Nat Med. 2024. PMID: 38266761
Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines.
Ghilardi G, Paruzzo L, Svoboda J, Chong EA, Shestov AA, Chen L, Cohen IJ, Gabrielli G, Nasta SD, Porazzi P, Landsburg DJ, Gerson JN, Carter J, Barta SK, Yelton R, Pajarillo R, Patel V, White G, Ballard HJ, Weber E, Napier E, Chong ER, Fraietta JA, Garfall AL, Porter DL, Milone MC, O'Connor R, Schuster SJ, Ruella M. Ghilardi G, et al. Among authors: paruzzo l. Blood Adv. 2024 Feb 13;8(3):653-666. doi: 10.1182/bloodadvances.2023011492. Blood Adv. 2024. PMID: 38113468 Free PMC article.
Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang Y, Patel RP, Kim KH, Cho H, Jo JC, Jeong SH, Oh SY, Choi YS, Kim SH, Lee JH, Angelos M, Guruprasad P, Cohen I, Ugwuanyi O, Lee YG, Pajarillo R, Cho JH, Carturan A, Paruzzo L, Ghilardi G, Wang M, Kim S, Kim SM, Lee HJ, Park JH, Cui L, Lee TB, Hwang IS, Lee YH, Lee YJ, Porazzi P, Liu D, Lee Y, Kim JH, Lee JS, Yoon DH, Chung J, Ruella M. Zhang Y, et al. Among authors: paruzzo l. Mol Cancer. 2023 Dec 9;22(1):200. doi: 10.1186/s12943-023-01886-9. Mol Cancer. 2023. PMID: 38066564 Free PMC article.
CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma.
Giraudo L, Cattaneo G, Gammaitoni L, Iaia I, Donini C, Massa A, Centomo ML, Basiricò M, Vigna E, Pisacane A, Picciotto F, Berrino E, Marchiò C, Merlini A, Paruzzo L, Poletto S, Caravelli D, Biolato AM, Bortolot V, Landoni E, Ventin M, Ferrone CR, Aglietta M, Dotti G, Leuci V, Carnevale-Schianca F, Sangiolo D. Giraudo L, et al. Among authors: paruzzo l. J Exp Clin Cancer Res. 2023 Nov 22;42(1):310. doi: 10.1186/s13046-023-02884-x. J Exp Clin Cancer Res. 2023. PMID: 37993874 Free PMC article.
Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies.
Ang Z, Paruzzo L, Hayer KE, Schmidt C, Torres Diz M, Xu F, Zankharia U, Zhang Y, Soldan S, Zheng S, Falkenstein CD, Loftus JP, Yang SY, Asnani M, King Sainos P, Pillai V, Chong E, Li MM, Tasian SK, Barash Y, Lieberman PM, Ruella M, Schuster SJ, Thomas-Tikhonenko A. Ang Z, et al. Among authors: paruzzo l. Blood. 2023 Nov 16;142(20):1724-1739. doi: 10.1182/blood.2023020400. Blood. 2023. PMID: 37683180 Free PMC article.
17 results